Comparison of pan-immune-inflammation value with other inflammation markers of long-term survival after ST-segment

Related Experiment Video

Updated: Aug 29, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.4K

Bektas Murat1, Selda Murat2, Mehmet Ozgeyik1

  • 1Eskisehir City Hospital, Department of Cardiology, Eskisehir, Turkey.

European Journal of Clinical Investigation
|September 13, 2022
PubMed

Insights

The Pan-Immune-Inflammation Value (PIV) effectively predicts mortality in ST-elevation myocardial infarction (STEMI) patients, outperforming other inflammatory markers. Further research is recommended to validate this finding.

Area of Science:

  • Cardiology
  • Inflammation Research
  • Biomarker Discovery

Background:

  • Atherosclerosis, a key driver of coronary artery disease, involves a significant inflammatory response.
  • Inflammatory markers are increasingly recognized for their prognostic value in cardiovascular diseases.

Purpose of the Study:

  • To evaluate the association between the Pan-Immune-Inflammation Value (PIV) and mortality in patients diagnosed with ST-elevation myocardial infarction (STEMI).
  • To compare the predictive performance of PIV against other established inflammation-based scores.

Main Methods:

  • Retrospective analysis of 658 STEMI patients who underwent percutaneous coronary intervention (PCI) between 2018 and 2022.
  • Calculation and comparison of PIV with other inflammatory indices, including neutrophil-lymphocyte ratio and platelet-lymphocyte ratio.
  • Primary outcome assessed was one-year all-cause mortality.

Main Results:

  • The study population comprised 76.9% males with a mean age of 58.7 years.
  • The Pan-Immune-Inflammation Value (PIV) demonstrated superior predictive ability for both primary and secondary outcomes compared to other inflammation markers.
  • Mean follow-up duration was 18.8 months.

Conclusions:

  • The Pan-Immune-Inflammation Value (PIV) emerges as a potent predictor of mortality in STEMI patients.
  • Further prospective studies are warranted to confirm the clinical utility of PIV as a prognostic biomarker in STEMI.
Abstract

Keywords:
neutrophil-to-lymphocyte ratio (NLR)pan- immune inflammation value (PIV)platelet-to-lymphocyte ratio (PLR)segment elevation myocardial infarction (ST)systemic immune-inflammation (SII)

More Related Videos

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.2K
An Intact Pericardium Ischemic Rodent Model07:15

An Intact Pericardium Ischemic Rodent Model

Published on: September 2, 2021

2.6K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
288
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
19
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
192
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
23
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
21